论文部分内容阅读
选择性增殖腺病毒dl15 2 0是一种新型的进入Ⅲ期临床研究的肿瘤基因病毒治疗药物 ,本文综述了dl15 2 0的发现、结构、实验研究和作用机理、临床试验研究疗效以及研究方向和展望
The selective adenovirus dl1520 is a new type of tumor gene virus drug that enters the phase III clinical study. This review summarizes the discovery, structure, experimental and mechanism of action of dl1520, the efficacy of clinical trials and its research direction and Outlook